NASHVILLE, Tenn., Nov. 1, 2022
/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:
CPIX), a specialty pharmaceutical company, announced today that it
will release its third quarter 2022 financial results and provide a
company update after the market closes on Tuesday, Nov. 8, 2022.
A conference call will be held Nov.
8 at 4:30 p.m. Eastern Time to
discuss the results. To participate in the call, please register at
https://register.vevent.com/register/BI21ae99e384c446cfb00fbab05f8bf1a3.
Once registered, participants can dial in from their phone using a
dial-in and PIN number that will be provided to them.
Alternatively, they can choose a "Call Me" option to have the
system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be
accessed via Cumberland's website
or by visiting https://edge.media-server.com/mmc/p/cg5rqxms.
Cumberland Pharmaceuticals is the largest biopharmaceutical
company founded and headquartered in the Mid-South and is focused
on the delivery of high-quality, prescription brands designed to
improve patient care. The company develops, acquires, and
commercializes products for the hospital acute care,
gastroenterology, rheumatology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection,
for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for
the treatment of pain and fever;
- Kristalose® (lactulose) for oral
solution, a prescription laxative, for the treatment of
constipation;
- Omeclamox®-Pak, (omeprazole,
clarithromycin, amoxicillin) for the treatment of Helicobacter
pylori (H. pylori) infection and related duodenal ulcer
disease;
- RediTrex® (methotrexate) injection,
for the treatment of active rheumatoid, juvenile idiopathic and
severe psoriatic arthritis, as well as disabling psoriasis;
- Sancuso® (granisetron) transdermal
system, for the prevention of nausea and vomiting in patients
receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to
raise serum sodium levels in hospitalized patients with euvolemic
and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for
the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as
well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs
underway evaluating its ifetroban product candidate in patients
with cardiomyopathy associated with Duchenne Muscular Dystrophy
("DMD"), Systemic Sclerosis ("SSc") and Aspirin-Exacerbated
Respiratory Disease ("AERD").
For more information on Cumberland's approved products, including full
prescribing information, please visit links to the individual
product websites, which can be found on the company's website at
www.cumberlandpharma.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-third-quarter-2022-financial-results-301664992.html
SOURCE Cumberland Pharmaceuticals Inc.
